Text Size

Glaucomatous optic neuropathy treatment options: The promise of novel therapeutics, techniques and tools to help preserve vision

Sharif N.


  • 2018
  • Neural Regeneration Research
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Drug Delivery

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Department of Global Alliances and External Research, Global Ophthalmology Research and Development, Santen Incorporated, Emeryville, CA, United States; Department of Pharmaceutical Sciences, Texas Southern University, Houston, TX, United States; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, TX, United States; Department of Pharmacy Sciences, Creighton University, Omaha, NE, United States; Department of Surgery and Cancer, Imperial College of Science and Technology, St. Mary's Campus, London, United Kingdom

Related Publications

IDrugs and idevices discovery research: Preclinical assays, techniques, and animal model studies for ocular hypotensives and neuroprotectants

Sharif N.A.


Müller glia derived EVs promote neurite recovery of an enriched population of retinal ganglion like cells derived from hESC retinal organoids after damage

Eastlake K, Lamb WDB, Tracey-White D, Shibagaki K, Khaw PT, Jayaram H, Limb GA


An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022